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Abstract 
A rare case of subependymoma in a young patient presenting with sensory dysesthesia is 
reported. Computed tomography scan and magnetic resonance imaging revealed a 
posterior fossa mass occluding the fourth ventricle with infiltration to the right side 
immediately behind the pontine tegmentum and impinging on the right spinothalamic 
tract. Postoperative tumor histopathology revealed the classical appearance of 
subependymoma. Subependymoma is a rare, asymptomatic, slow-growing, low-grade 
glioma of the central nervous system. If symptomatic, the clinical features are commonly 
secondary to hydrocephalus, but subependymoma presenting with sensory dysesthesia 
has never been reported in the literature. 
 
Introduction 
Subependymomas are uncommonly encountered ependymal tumors, accounting for 
less than 1% of all intracranial neoplasms and are distinguished from ordinary 
ependymomas by their overall better prognosis. Most of them are asymptomatic and 
detected incidentally at autopsy. It has been reported that there is 0.7% incidence of 
subependymoma among 1,000 patients with pathologically proven intracranial neoplasms 
[1]. When symptomatic, subependymomas often obstruct critical portions of the 
cerebrospinal fluid pathway, causing hydrocephalus. The most common symptoms 
include headache, gait ataxia, vertigo or dizziness, nausea and vomiting [2]. Here, we 
present a case of symptomatic subependymoma with a very rare clinical presentation. Case Rep Neurol 2011;3:227–232 
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Case Presentation 
A 19-year-old male presented to us with complaints of pain and numbness of 1 month’s duration on 
the left side of his body, including the face and the upper and lower extremities. He reported no 
significant medical antecedent history. This complaint was preceded by herpes zoster involving the V3 
distribution of the trigeminal nerve. The lesions completely disappeared after treatment, but the pain 
and numbness persisted. He was treated with Pregabalin for the pain without any response. Clinical 
examination revealed decreased perception of pain and touch involving the whole left side of his body. 
The rest of the detailed neurological examination was normal. 
With the suspicion of central pathology, magnetic resonance imaging (MRI) of the brain with 
gadolinium was carried out which revealed presence of a posterior fossa mass (fig. 1, fig. 2). The mass 
was almost occluding the fourth ventricle with infiltration to the right side immediately behind the 
pontine tegmentum and probably impinging on the right spinothalamic tract causing the presenting 
symptoms. There was a central area of calcification and mild enhancement to the contrast. The patient 
underwent craniotomy and complete macroscopic removal of the tumor. Postoperative tumor 
histopathology revealed the classical appearance of subependymoma with characteristic clusters of 
nuclei in a dense fibrillary background (fig. 3). Mitotic activity, vascular proliferation or necrosis was 
not observed. Absence of perivascular pseudorosettes or true rosettes excluded the possibility of 
ependymoma. In the postoperative period, the patient remained pain free and no radiological evidence 
of recurrence was seen at follow-up after 1 year. 
Written informed consent was obtained from the patient for publication of this case report and 
accompanying images. 
 
Discussion 
Subependymoma is a rare, benign, slow-growing neoplasm that was first described by 
Scheinker [3] in 1945 as a tumor arising from the subependymal cell plate. 
Subependymomas are most commonly located in the fourth and lateral ventricles, but 
have also been reported arising in the third ventricle, septum pellucidum, and spinal 
canal. Since its original description, more than 100 case reports of intracranial 
subependymomas have been described. Due to its rarity and variable imaging 
characteristics, reliable preoperative diagnosis remains challenging [4]. 
Most subependymomas are smaller than 2 cm in diameter. However, symptomatic 
subependymomas are usually larger, averaging about 3–5 cm in greatest dimension [5, 6]. 
The clinical presentation is nonspecific. Most symptomatic patients (80%) present with 
symptoms related to hydrocephalus as a consequence of ventricular obstruction [7]. Less 
commonly, focal neurological deficits (27%), seizures (9%), and subarachnoid 
hemorrhage (4.5%) have been reported [7]. Males are more commonly affected and most 
reported cases (82%) have occurred in patients older than 15 years [7]. At least half of the 
reported cases have occurred in the fourth ventricle, with most of the remainder arising in 
the lateral ventricle [5]. Jooma et al. [8] reported a series of 12 cases of fourth ventricle 
subependymoma. The commonest symptoms were loss of balance (9/12) and vertigo 
(8/12). Nystagmus was the commonest sign (11/12). None of the cases presented with 
sensory dysesthesia.  
Commonly, patients with subependymomas have long duration and slow progression 
of symptoms. They usually present in the fifth or sixth decade of life [8]. In our case, 
striking features were short duration of atypical symptoms and early age of presentation. Case Rep Neurol 2011;3:227–232 
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Subependymomas have a white to grayish color and are well circumscribed with a firm 
texture [7]. The tumors grow in a slow deliberate fashion, are usually avascular, and are 
attached to the ventricular wall by a narrow pedicle [7]. Although the exact histogenesis is 
still uncertain, they most likely arise from subependymal glial cells. Other possible sites 
include astrocytes from the subependymal plate, ependymal cells, and a mixture of 
ependymal and astrocytic cells. In our case, characteristic clusters of nuclei in a dense 
fibrillary background were observed. 
Common imaging characteristics of subependymoma include a lobulated, well-defined 
intraventricular mass with no paraventricular extension [7, 9, 10]. The majority of 
subependymomas are solid or solid with areas of cystic degeneration [1, 7]. Calcification 
is common, occurring in 32–50% of cases [7, 8]. Computed tomography (CT) 
enhancement characteristics of subependymoma are variable ranging from absent to 
marked enhancement [1, 7, 9, 10]. In our case, there was central calcification, minimal 
enhancement to contrast and paraventricular extension. 
MRI characteristics commonly include a well-defined solid or mixed solid and cystic 
intraventricular mass. The solid component is hypo- or isointense on T1-weighted images 
and hyperintense on T2-weighted images [1, 7, 9, 10]. The heterogeneous signal 
commonly seen in subependymomas correlates well with histopathologic findings, 
including necrosis, calcification, microcystic change, and hemorrhage [11]. Peritumoral 
edema is an infrequent feature. Similar to CT, MRI enhancement characteristics are 
variable, including absent to intense enhancement [7, 11]. MRI has proven most useful in 
defining the size and extent of the tumor, as well as its relationship to other anatomical 
structures, such as vasculature, playing a critical role in preoperative planning [8]. 
Included in the differential diagnosis of fourth ventricular masses are ependymoma, 
subependymoma, choroid plexus papilloma, metastasis, rarely meningioma, central 
neurocytoma and subependymal giant cell astrocytcoma. Age, location and imaging 
features are helpful in narrowing the number of differential diagnoses. 
In attempting to differentiate subependymomas from ependymomas with imaging 
studies alone, Lobato et al. [7] noted that subependymomas tend to be intraventricular, 
whereas ependymomas tend be paraventricular. They also reported that hyperattenuation 
compared with brain parenchyma, enhancement, calcification, and cyst formation was 
also more commonly seen in ependymomas than in subependymomas. However, none of 
these features are sufficiently pronounced to be pathognomonic for either lesion. Like in 
our case, the tumor was paraventricular, which raised the suspicion in favor of 
ependymoma preoperatively. Therefore, the distinctions between these tumors are even 
less apparent when they arise in the fourth ventricle [7]. 
Choroid plexus papillomas most commonly occur in young patients and intensely 
enhance after contrast administration [4]. Central neurocytomas are similar to 
subependymomas in their cystic appearance but are usually isointense with gray matter 
on both T1- and T2-weighted sequences, whereas subependymomas are almost always 
hyperintense on T2-weighted images [7]. 
Subependymal giant cell astrocytomas always occur near the foramen of Monro, calcify 
frequently, enhance intensely, and are often associated with ventricular wall calcification 
[4, 7]. Similarly, meningiomas frequently calcify and intensely enhance. Metastasis and 
malignant gliomas are more likely to grow rapidly and often lack calcification [8]. Case Rep Neurol 2011;3:227–232 
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Optimal therapy for symptomatic subependymomas is complete surgical excision. This 
can often be achieved with supratentorial subependymomas, given that these tumors are 
usually well demarcated, avascular, and noninvasive [1, 7, 10]. Fourth ventricle 
subependymomas, however, frequently arise from the floor of the fourth ventricle and the 
likelihood of cranial nerve injury often precludes complete surgical resection [1, 8, 10]. 
Perioperative mortality rates as high as 42% have been reported with surgical resection of 
fourth ventricle subependymomas [8]. In cases of symptomatic fourth ventricle 
subependymomas where complete resection cannot be achieved, surgery should be 
directed towards debulking and improving CSF outflow [8, 10]. 
Most authors do not advocate postoperative radiation therapy after complete surgical 
resection of pure subependymoma as there is a good prognosis with surgery alone [7, 9, 
10]. Lombardi et al. [10] reported follow-up data in 21 patients who underwent surgery 
for subependymoma and found that, of the 19 patients who survived the perioperative 
period, 12 underwent gross total resection with no evidence of tumor recurrence or 
tumor-related death. The remaining 7 patients were treated with radiation therapy and 
follow-up imaging demonstrated a greater radiographic response at doses of 5,000 cGy or 
greater, supporting an argument for radiation therapy in patients with residual tumor or 
evidence or tumor progression [10]. In our case, the tumor was well localized with 
minimal paraventricular spread and without cranial nerves involvement, which 
influenced the better surgical outcome. 
Conclusion 
We conclude that subependymomas are rare, often asymptomatic masses related to the 
ventricular system. Intraventricular subependymomas have some distinguishing clinical 
features as well as MRI and CT characteristics, but none of them is pathognomic. The best 
treatment for subependymomas is total resection and, if this is not possible, debulking of 
the tumor followed by radiation therapy can be considered. Diagnosis of 
subependymoma can be easily missed in view of such atypical presentation. A high index 
of suspicion is required to clinch the diagnosis early in the process because of its excellent 
prognosis with timely treatment. 
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Fig. 1. MRI of the brain with gadolinium (sagittal section). Mass in the fourth ventricle with minimum 
enhancement and central calcification (confirmed by CT of the head). 
 
 
 
Fig. 2. MRI of the brain (axial section). Mass in the fourth ventricle with minimal paraventricular 
spread. 
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Fig. 3. Postoperative histopathology of the mass showing characteristic clusters of nuclei in a dense 
fibrillary background suggestive of subependymoma. 
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